You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Investigators used gene panel sequence data to look at rare de novo variant frequencies in potential risk genes for neurodevelopmental disorders with epilepsy.
The company's assay relies on a set of 15 methylation and microRNA markers to determine whether a woman has breast cancer.
As part of the collaboration, B. Braun China founded a subsidiary, called B. Braun Precision Medicine Technology (BBPM), that opened in Shanghai in May.
The German company validated the panel, which focuses on actionable results, in a 300-participant clinical study in collaboration with Robert-Bosch-Hospital in Stuttgart.
With the new certification in hand, the company plans to expand its business in the US through its Pennsylvania-based subsidiary, B. Braun CeGaT.
The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.
Revisions to the reimbursement catalog went into effect July 1, but stakeholders are quarreling about a pre-authorization requirement in court.
Over the last half year, CeGaT lowered turnaround times and prices for its assays, and its lab recently passed CAP inspection.
A medical genetics practice's lawsuit against a government insurance administrator points to continued uncertainty about reimbursement for NGS testing in Germany.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.